J
Jan Lewis Brandes
Researcher at Vanderbilt University
Publications - 65
Citations - 5385
Jan Lewis Brandes is an academic researcher from Vanderbilt University. The author has contributed to research in topics: Migraine & Population. The author has an hindex of 35, co-authored 64 publications receiving 4629 citations.
Papers
More filters
Journal ArticleDOI
Topiramate for migraine prevention: a randomized controlled trial.
Jan Lewis Brandes,Joel R. Saper,Merle L. Diamond,James R. Couch,Donald W. Lewis,Jennifer Schmitt,Walter Neto,Stefan Schwabe,David R. Jacobs +8 more
TL;DR: Topiramate showed significant efficacy in migraine prevention within the first month of treatment, an effect maintained for the duration of the double-blind phase.
Journal ArticleDOI
Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial
Stewart J. Tepper,Messoud Ashina,Uwe Reuter,Jan Lewis Brandes,David Doležil,Stephen D. Silberstein,Paul Winner,Dean Leonardi,Daniel D. Mikol,Robert A. Lenz +9 more
TL;DR: In patients with chronic migraine, erenumab 70 mg and 140 mg reduced the number of monthly migraine days with a safety profile similar to placebo, providing evidence that erenUMab could be a potential therapy for migraine prevention.
Journal ArticleDOI
Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial.
Stephen D. Silberstein,Richard B. Lipton,David W. Dodick,Frederick G. Freitag,Nabih M. Ramadan,Ninan T. Mathew,Jan Lewis Brandes,Marcelo E. Bigal,Joel Saper,Steven Ascher,Donna Jordan,Steven J. Greenberg,Joseph Hulihan +12 more
TL;DR: The objective was to evaluate the efficacy and safety of topiramate (100 mg/day) compared with placebo for the treatment of chronic migraine.
Journal ArticleDOI
ARISE: A Phase 3 randomized trial of erenumab for episodic migraine:
David W. Dodick,Messoud Ashina,Jan Lewis Brandes,David Kudrow,Michel Lanteri-Minet,V. V. Osipova,Kerry Palmer,Hernan Picard,Daniel D. Mikol,Robert A. Lenz +9 more
TL;DR: As a preventive treatment of episodic migraine, erenumab at a dosage of 70 mg monthly significantly reduced migraine frequency and acute migraine-specific medication use.
Journal ArticleDOI
Sumatriptan-naproxen for acute treatment of migraine: a randomized trial.
Jan Lewis Brandes,David Kudrow,Stuart R. Stark,C. Phillip O’Carroll,James U. Adelman,Francis J. O'Donnell,W. James Alexander,Susan E. Spruill,Pamela S. Barrett,Shelly E. Lener +9 more
TL;DR: Sumatriptan, 85 mg, plus naproxen sodium, 500 mg, as a single tablet for acute treatment of migraine resulted in more favorable clinical benefits compared with either monotherapy, with an acceptable and well-tolerated adverse effect profile.